Alexion Pharmaceuticals Inc. Release: Researchers to Present New Data on Soliris® (eculizumab) as a Treatment for Patients with aHUS at American Society of Nephrology Annual Meeting
Published: Oct 16, 2013
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers are scheduled to present data from clinical studies of Soliris® (eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS), a genetic, life-long, ultra-rare disease associated with vital organ failure and premature death.
Help employers find you! Check out all the jobs and post your resume.